NO20053529L - Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler - Google Patents

Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler

Info

Publication number
NO20053529L
NO20053529L NO20053529A NO20053529A NO20053529L NO 20053529 L NO20053529 L NO 20053529L NO 20053529 A NO20053529 A NO 20053529A NO 20053529 A NO20053529 A NO 20053529A NO 20053529 L NO20053529 L NO 20053529L
Authority
NO
Norway
Prior art keywords
combination
beta receptor
lymphotoxin
chemotherapeutic agents
receptor drugs
Prior art date
Application number
NO20053529A
Other languages
English (en)
Other versions
NO20053529D0 (no
Inventor
Doreen Lepage
Aaln Gill
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20053529D0 publication Critical patent/NO20053529D0/no
Publication of NO20053529L publication Critical patent/NO20053529L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

S A M M E N D R A G Denne oppfinnelsen presenterer kombinasjonsterapier som inkluderer en sammensetning som aktiverer lymfotoksin-beta-reseptorsignalering i kombinasjon med et eller flere andre kjemoterapeutiske midler, så vel som terapeutiske fremgangsmåter og screeningsmetoder for å identifisere midler som i kombinasjon med et lymfotoksin-beta-reseptoragonistmiddel har en supra-additiv effekt på tumorinhibering.
NO20053529A 2002-12-20 2005-07-19 Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler NO20053529L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20
PCT/US2003/041243 WO2004058183A2 (en) 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Publications (2)

Publication Number Publication Date
NO20053529D0 NO20053529D0 (no) 2005-07-19
NO20053529L true NO20053529L (no) 2005-09-20

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053529A NO20053529L (no) 2002-12-20 2005-07-19 Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler

Country Status (16)

Country Link
US (1) US20060134102A1 (no)
EP (1) EP1585547A4 (no)
JP (1) JP2006513225A (no)
KR (1) KR20050094819A (no)
CN (1) CN1753692A (no)
AU (1) AU2003303339A1 (no)
BR (1) BR0317573A (no)
CA (1) CA2509495A1 (no)
EA (1) EA200501019A1 (no)
IS (1) IS7900A (no)
MX (1) MXPA05006663A (no)
NO (1) NO20053529L (no)
PL (1) PL377611A1 (no)
RS (1) RS20050481A (no)
WO (1) WO2004058183A2 (no)
ZA (1) ZA200505543B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
WO2002030986A2 (en) * 2000-10-13 2002-04-18 Biogen, Inc. HUMANIZED ANTI-LT-β-R ANTIBODIES
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
CA2490280A1 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP5068072B2 (ja) * 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
CA2655411A1 (en) * 2006-06-15 2007-12-21 Biogen Idec Ma Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
AR063257A1 (es) 2006-10-12 2009-01-14 Genentech Inc Anticuerpos anti-linfotoxina alfa
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2009004134A (es) * 2006-10-20 2009-08-12 Biogen Idec Inc Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
RU2770001C2 (ru) 2015-10-06 2022-04-14 Риджентс Оф Дзе Юниверсити Оф Миннесота Терапевтические соединения и способы
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
US20210253723A1 (en) * 2018-06-15 2021-08-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN117327174A (zh) * 2022-06-24 2024-01-02 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CN1900116A (zh) * 1995-01-26 2007-01-24 拜奥根Idec马萨诸塞公司 抗－LT－β－R抗体、含有该抗体的药用组合物及其制药应用
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
IL129527A (en) * 1996-10-25 2006-12-10 Biogen Idec Inc Pharmaceutical preparations containing soluble lymphoxine-beta receptors
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002030986A2 (en) * 2000-10-13 2002-04-18 Biogen, Inc. HUMANIZED ANTI-LT-β-R ANTIBODIES
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途

Also Published As

Publication number Publication date
EP1585547A2 (en) 2005-10-19
CN1753692A (zh) 2006-03-29
NO20053529D0 (no) 2005-07-19
KR20050094819A (ko) 2005-09-28
PL377611A1 (pl) 2006-02-06
CA2509495A1 (en) 2004-07-15
MXPA05006663A (es) 2005-09-30
RS20050481A (en) 2007-08-03
AU2003303339A1 (en) 2004-07-22
IS7900A (is) 2005-06-20
ZA200505543B (en) 2006-12-27
WO2004058183A2 (en) 2004-07-15
EA200501019A1 (ru) 2006-06-30
US20060134102A1 (en) 2006-06-22
EP1585547A4 (en) 2006-10-25
WO2004058183A3 (en) 2004-12-09
JP2006513225A (ja) 2006-04-20
BR0317573A (pt) 2005-11-22

Similar Documents

Publication Publication Date Title
NO20053529L (no) Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler
Jensen et al. A juvenile form of postsynaptic hippocampal long‐term potentiation in mice deficient for the AMPA receptor subunit GluR‐A
NO20073293L (no) Toll-liknende reseptor-3-antagonister, fremgangsmater og anvendelser
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
TW200731968A (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
NO20010446L (no) Substituert anilidforbindelser og metoder
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
Alvarez et al. Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat
Sperr et al. Diagnosis, progression patterns and prognostication in mastocytosis
NO20013641L (no) BAFF, relaterte blokkeringsmidler samt anvendelse derav ved stimulering og inhibering av B-celler og immunoglobuliner iimmunresponser
BRPI0507808A (pt) métodos de modular a atividade de citocina; reagentes relacionados
NO20050827L (no) Anvendelse av interferon-B ved behandling av nyresvikt
WO2007146414A3 (en) Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
Ifergan et al. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
ES2125567T3 (es) Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.
WO2007013997A3 (en) Inhibition of the raf/mek/p-erk pathway for treating cancer
CY1114307T1 (el) Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν
Marazziti et al. Citalopram in refractory obsessive-compulsive disorder: an open study
BRPI0416812A (pt) métodos e reagentes para o tratamento de desordens inflamatórias
AR044452A1 (es) Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa
Peeters et al. Potential effect modifiers of the association between physical activity patterns and joint symptoms in middle‐aged women
WO2008021048A3 (en) Adp-ribosyltransferase based methods and compositions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application